#1 Clinical Trials Search in Europe

Favezelimab

Favezelimab is an investigational drug being studied in clinical trials for various types of cancer. This article provides an overview of ongoing research examining favezelimab alone and in combination with other therapies for treating advanced cancers like non-small cell lung cancer, colorectal cancer, lymphomas, and more. We’ll explore the key objectives, eligibility criteria, and potential benefits being evaluated in these cutting-edge clinical studies.

Table of Contents

What is Favezelimab?

Favezelimab is a new type of cancer drug that is currently being studied in clinical trials. It is also known by other names such as MK-4280, anti-LAG3 monoclonal antibody MK-4280, and mavezelimab[1]. Favezelimab is a type of immunotherapy, which means it works by helping your body’s own immune system fight cancer cells.

How Does Favezelimab Work?

Favezelimab works by targeting a protein called LAG-3 (Lymphocyte-activation gene 3) on immune cells[2]. LAG-3 is what’s known as an immune checkpoint, which normally helps prevent the immune system from attacking healthy cells. However, some cancer cells can use LAG-3 to hide from the immune system. By blocking LAG-3, favezelimab helps the immune system recognize and attack cancer cells more effectively.

Cancers Being Studied

Favezelimab is being investigated for use in several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is a type of lung cancer that accounts for most lung cancer cases[1].
  • Colorectal cancer: This is cancer that starts in the colon or rectum[2].
  • Non-muscle invasive bladder cancer (NMIBC): This is a type of bladder cancer that has not spread into the muscle layer of the bladder wall[3].
  • Hematologic malignancies: These are cancers that affect the blood, bone marrow, and lymph nodes[4].
  • Classical Hodgkin lymphoma: This is a type of cancer that starts in white blood cells called lymphocytes[5].
  • Esophageal squamous cell carcinoma (ESCC): This is a type of cancer that affects the esophagus, the tube that connects the throat to the stomach[6].

Combination Therapies

In many of the ongoing studies, favezelimab is being tested in combination with other cancer treatments. One common combination is with pembrolizumab, another immunotherapy drug. This combination is often referred to as MK-4280A[7]. Other combinations being studied include:

  • Favezelimab with pembrolizumab and lenvatinib (for non-small cell lung cancer)[1]
  • Favezelimab with pembrolizumab and chemotherapy (for various cancers)[6]

The idea behind these combinations is that they might work better together than any single treatment alone.

Potential Benefits

While research is still ongoing, early studies suggest that favezelimab, especially when combined with other treatments, may have several potential benefits:

  • Improved response rates: More patients may see their tumors shrink or disappear[2].
  • Longer progression-free survival: Patients may go longer without their cancer getting worse[5].
  • Better overall survival: Patients may live longer overall[5].
  • Potential to help patients who haven’t responded to other treatments: Favezelimab might work in patients whose cancer has resisted other forms of immunotherapy[5].

Side Effects and Safety

As with all cancer treatments, favezelimab can cause side effects. Common side effects of immunotherapy drugs like favezelimab can include:

  • Fatigue
  • Skin rashes
  • Diarrhea
  • Nausea

More serious side effects can occur if the immune system attacks healthy parts of the body. These can include inflammation in the lungs, liver, or other organs[3]. It’s important to note that not everyone experiences these side effects, and many can be managed with proper medical care.

Ongoing Research

Favezelimab is still being studied in clinical trials, which are research studies that test new treatments to see how well they work and how safe they are. These trials are looking at favezelimab in different types of cancer, in different combinations with other drugs, and at different stages of treatment[1][2][3][4][5][6].

If you’re interested in learning more about clinical trials involving favezelimab, you can talk to your doctor or visit websites that list clinical trials, such as clinicaltrials.gov.

Conclusion

Favezelimab represents an exciting new approach in cancer treatment. By helping the immune system fight cancer more effectively, it has the potential to improve outcomes for patients with various types of cancer. However, it’s important to remember that research is still ongoing, and favezelimab is not yet approved for general use. As with any medical treatment, the potential benefits must be weighed against the possible risks. Always consult with your healthcare provider for personalized medical advice.

Aspect Details
Drug Name Favezelimab (MK-4280)
Combination Therapy Often studied with pembrolizumab (MK-3475) as MK-4280A
Cancer Types Studied Non-small cell lung cancer, colorectal cancer, classical Hodgkin lymphoma, bladder cancer, esophageal cancer, other solid tumors and blood cancers
Administration Method Intravenous infusion
Key Objectives Evaluate safety, tolerability, and efficacy (tumor response, survival outcomes)
Trial Phases Phase 1, 2, and 3 studies ongoing
Common Eligibility Criteria Adult patients with advanced cancers, often after progression on standard therapies
Key Endpoints Objective response rate, progression-free survival, overall survival, adverse events

FAQ

  • What types of cancer is favezelimab being studied for? Favezelimab is being investigated for multiple cancer types, including non-small cell lung cancer, colorectal cancer, classical Hodgkin lymphoma, bladder cancer, and other solid tumors and hematologic malignancies.
  • How is favezelimab administered? Favezelimab is typically administered as an intravenous infusion, often in combination with other cancer therapies like pembrolizumab.
  • What are the main goals of the favezelimab clinical trials? The main goals include evaluating the safety, tolerability, and efficacy of favezelimab alone or in combination with other treatments. Researchers are looking at outcomes like tumor response rates, progression-free survival, and overall survival.
  • Who may be eligible to participate in these clinical trials? Eligibility varies by study, but generally includes adult patients with specific advanced cancers who meet certain health criteria. Some trials focus on patients whose cancer has progressed after standard treatments.
  • What are some potential side effects being monitored? While specific side effects can vary, researchers are closely monitoring for any adverse events, particularly those related to the immune system. Common side effects of similar drugs may include fatigue, nausea, and skin reactions.

Ongoing Clinical Trials on Favezelimab

  • Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Estonia Finland +15

  • Study on the Safety and Effectiveness of Pembrolizumab, Favezelimab, and Vibostolimab for Children and Young Adults with Blood Cancers or Solid Tumors

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Italy

  • Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Greece Hungary Italy Poland Spain

  • Study of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Hungary The Netherlands Poland Spain

  • Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland Spain

  • Study on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Hungary Italy Poland Spain

  • Study of MK-4280A (Favezelimab and Pembrolizumab) for Patients with Metastatic Colorectal Cancer After Previous Treatment

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Norway Spain

  • Study on the Safety and Effects of Favezelimab and Pembrolizumab for Patients with Blood Cancers

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany Greece Hungary Italy

  • Study of Favezelimab Combined with Pembrolizumab (MK-4280A) for Patients with Selected Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands

Glossary

  • Favezelimab: An investigational drug being studied for cancer treatment that targets a protein called LAG-3 on immune cells.
  • Pembrolizumab: An immunotherapy drug that works by helping the immune system detect and fight cancer cells.
  • MK-4280A: A combination therapy containing both favezelimab and pembrolizumab.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Dose-Limiting Toxicity (DLT): Side effects severe enough to prevent giving a higher dose of a treatment.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer treatment works.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.

References

  1. http://clinicaltrials.eu/trial/study-of-pembrolizumab-favezelimab-and-lenvatinib-for-patients-with-advanced-non-small-cell-lung-cancer/
  2. http://clinicaltrials.eu/trial/study-comparing-mk-1308a-and-pembrolizumab-for-patients-with-advanced-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency/
  3. http://clinicaltrials.eu/trial/study-of-pembrolizumab-vibostolimab-and-favezelimab-for-patients-with-high-risk-non-muscle-invasive-bladder-cancer-unresponsive-to-bcg-therapy/
  4. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-favezelimab-and-pembrolizumab-for-patients-with-blood-cancers/
  5. http://clinicaltrials.eu/trial/study-comparing-mk-4280a-favezelimab-and-pembrolizumab-with-chemotherapy-for-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma/
  6. http://clinicaltrials.eu/trial/study-of-pembrolizumab-and-drug-combination-for-patients-with-advanced-esophageal-cancer/
  7. http://clinicaltrials.eu/trial/study-of-mk-4280a-pembrolizumab-and-lenvatinib-for-treating-advanced-cancer-in-adults/